Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Oligomeganephronia Follow-up

  • Author: Pascale H Lane, MD; Chief Editor: Craig B Langman, MD  more...
 
Updated: Dec 28, 2014
 

Further Outpatient Care

See the list below:

  • Long-term follow-up care
    • Oligomeganephronia is a chronic progressive renal disease that leads invariably to renal failure.
    • Assessment of renal function, biochemical status, and growth is necessary to manage this condition and to provide optimal care.
    • Fuke et al reported a case of a 23-year-old man with oligomeganephronia that did not progress to end-stage renal failure. Clinical features included renal insufficiency, persistent proteinuria, and bilateral small kidneys. Renal pathology revealed greatly enlarged glomeruli (mean diameter, 325 μm, which was approximately 2 times larger than normal).[3]
Next

Complications

See the list below:

  • Complications of chronic renal disease include growth failure, metabolic bone disease, anemia, metabolic acidosis, and other disorders of fluid and electrolyte metabolism.
Previous
Next

Prognosis

See the list below:

  • Oligomeganephronia is progressive and results in chronic renal failure and end-stage renal disease (ESRD).
Previous
Next

Patient Education

See the list below:

  • Patients with oligomeganephronia and their parents or caregivers need to understand the chronic progressive nature of this condition and the need for long-term follow-up care to maximize growth and to prolong renal function.
  • If an associated syndrome is present, offer genetic counseling and education to the patient and family.
Previous
 
Contributor Information and Disclosures
Author

Pascale H Lane, MD Helen Freytag Distinguished Professor of Pediatrics and Associate Chair for Research, Department of Pediatrics, Section of Nephrology, University of Nebraska Medical Center; Editor-in-Chief, American Society of Nephrology Kidney News

Pascale H Lane, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association for Physician Leadership, American Diabetes Association, American Heart Association, American Physiological Society, JDRF, American Society of Nephrology, American Society of Pediatric Nephrology, International Society of Nephrology, National Kidney Foundation

Disclosure: Received consulting fee from Amag Pharmaceuticals for data safety monitoring board.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Luther Travis, MD Professor Emeritus, Departments of Pediatrics, Nephrology and Diabetes, University of Texas Medical Branch School of Medicine

Luther Travis, MD is a member of the following medical societies: Alpha Omega Alpha, American Federation for Medical Research, International Society of Nephrology, Texas Pediatric Society

Disclosure: Nothing to disclose.

Chief Editor

Craig B Langman, MD The Isaac A Abt, MD, Professor of Kidney Diseases, Northwestern University, The Feinberg School of Medicine; Division Head of Kidney Diseases, The Ann and Robert H Lurie Children's Hospital of Chicago

Craig B Langman, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Nephrology, International Society of Nephrology

Disclosure: Received income in an amount equal to or greater than $250 from: Alexion Pharmaceuticals; Raptor Pharmaceuticals; Eli Lilly and Company; Dicerna<br/>Received grant/research funds from NIH for none; Received grant/research funds from Raptor Pharmaceuticals, Inc for none; Received grant/research funds from Alexion Pharmaceuticals, Inc. for none; Received consulting fee from DiCerna Pharmaceutical Inc. for none.

Additional Contributors

Richard Neiberger, MD, PhD Director of Pediatric Renal Stone Disease Clinic, Associate Professor, Department of Pediatrics, Division of Nephrology, University of Florida College of Medicine and Shands Hospital

Richard Neiberger, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Federation for Medical Research, American Medical Association, American Society of Nephrology, American Society of Pediatric Nephrology, Christian Medical and Dental Associations, Florida Medical Association, International Society for Peritoneal Dialysis, International Society of Nephrology, National Kidney Foundation, New York Academy of Sciences, Shock Society, Sigma Xi, Southern Medical Association, Southern Society for Pediatric Research, Southwest Pediatric Nephrology Study Group

Disclosure: Nothing to disclose.

References
  1. Zaffanello M, Brugnara M, Franchini M, Fanos V. TCF2 gene mutation leads to nephro-urological defects of unequal severity: an open question. Med Sci Monit. 2008 Jun. 14(6):RA78-86. [Medline]. [Full Text].

  2. [Guideline] Bush WH Jr, Choyke PL, Bluth RI, et al. Renal failure. ACR Appropriateness Criteria. 2005. [Full Text].

  3. Fuke Y, Hemmi S, Kajiwara M, Yabuki M, Fujita T, Soma M. Oligomeganephronia in an adult without end stage renal failure. Clin Exp Nephrol. 2012 Apr. 16(2):325-8. [Medline].

  4. Bohn S, Thomas H, Turan G, et al. Distinct molecular and morphogenetic properties of mutations in the human HNF1beta gene that lead to defective kidney development. J Am Soc Nephrol. 2003 Aug. 14(8):2033-41. [Medline]. [Full Text].

  5. Broyer M, Soto B, Gagnadoux MF, et al. Oligomeganephronic renal hypoplasia. Adv Nephrol Necker Hosp. 1997. 26:47-63. [Medline].

  6. Drukker A. Oligonephropathy: from a rare childhood disorder to a possible healthproblem in the adult. Isr Med Assoc J. 2002 Mar. 4(3):191-5. [Medline].

  7. Janin-Mercier A, Palcoux JB, Gubler MC, et al. Oligomeganephronic renal hypoplasia with tapetoretinal degeneration. Report of one case with ultrastructural study of the renal biopsy. Virchows Arch A Pathol Anat Histopathol. 1985. 407(4):477-83. [Medline].

  8. Miltenyi M, Czeizel AE, Balogh L, Detre Z. Autosomal recessive acrorenal syndrome. Am J Med Genet. 1992 Jul 15. 43(5):789-90. [Medline].

  9. Sagen JV, Bostad L, Njolstad PR, Sovik O. Enlarged nephrons and severe nondiabetic nephropathy in hepatocyte nuclear factor-1beta (HNF-1beta) mutation carriers. Kidney Int. 2003 Sep. 64(3):793-800. [Medline].

  10. Salomon R, Tellier AL, Attie-Bitach T, et al. PAX2 mutations in oligomeganephronia. Kidney Int. 2001 Feb. 59(2):457-62. [Medline].

  11. Van Acker KJ, Roodhooft AM, Melis K. Monozygotic twins non-concordant for oligomeganephronic renal hypoplasia: artery-vein placental shunting as a possible pathogenetic mechanism. Clin Nephrol. 1986 Mar. 25(3):165-8. [Medline].

  12. Widdershoven J, Monnens L, Assmann K, Cremmers C. Renal disorders in the branchio-oto-renal syndrome. Helv Paediatr Acta. 1983 Dec. 38(5-6):513-22. [Medline].

Previous
Next
 
Renal sonogram of a newborn with spontaneous pneumothorax, preauricular pits, and branchial cysts. The right kidney was absent, and the left kidney was hyperechoic and hypoplastic. The left kidney's length measured 1.8 cm; kidneys in newborns are normally 4.5 cm.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.